Patients with a history of herpes zoster ophthalmicus (HZO) face a twofold increase in the risk of recurrence during the first eight weeks following a shingles vaccination, according to data presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Researchers at Kaiser Permanente Northern California found that while the absolute incidence of recurrence remains low, the timing of vaccination relative to an initial HZO diagnosis appears to be a critical factor in patient safety.
How does shingles vaccination impact HZO recurrence?
The study, which utilized a self-controlled risk interval (SCRI) analysis, compared the incidence of HZO recurrence in the 56 days immediately following vaccination against a subsequent 56-day control period. Researchers identified an incidence rate ratio (IRR) of 2.05, indicating that patients were twice as likely to experience a recurrence in the initial eight-week window after receiving a shingles vaccine compared to the following eight weeks.
The cohort included 10,018 patients aged 50 and older who had been diagnosed with HZO between 2010 and 2023. Of that group, 2,900 individuals received a shingles vaccine during the study period. Across the full 112-day observation window, 38 cases of recurrent HZO were documented.
HZO occurs when the varicella zoster virus reactivates along the ophthalmic branch of the trigeminal nerve. This can lead to severe ocular complications, including uveitis, keratitis, optic neuropathy, and, in some cases, permanent vision loss.
Why is the timing of vaccination important for HZO patients?
The data revealed a significant gap in the timeline between an initial HZO diagnosis and the administration of the vaccine. Patients who experienced a recurrence were vaccinated a median of 309 days after their initial HZO diagnosis. In contrast, those who did not experience a recurrence were vaccinated a median of 991 days after their diagnosis.
Furthermore, 89% of the patients who suffered a recurrence had pre-existing ocular involvement prior to their vaccination, compared to 42% of the non-recurrence group. This suggests that vaccinating patients while their initial HZO episode may still be clinically active or recent increases the risk of triggering a new flare-up.
What are the current clinical considerations for vaccination?
Currently, the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) recommends the recombinant zoster vaccine (Shingrix) for immunocompetent adults aged 50 and older. While existing guidelines mandate an eight-week interval between doses of the live zoster vaccine and the recombinant vaccine, there is currently no established guidance on how long a patient should wait after an incident HZO diagnosis before receiving the shingles vaccine.
The authors of the Kaiser Permanente study suggest that clinicians should exercise increased vigilance regarding vaccination timing for patients with a history of HZO. Specifically, providers are encouraged to counsel patients on monitoring for symptoms in the weeks immediately following a dose.
Study limitations and future outlook
As the findings were presented as an abstract, full peer-reviewed methods and sensitivity analyses are not yet available. Several factors may influence the generalizability of the results, including the fact that the cohort was drawn from a single integrated health system. Additionally, the primary analysis combined data from both the live zoster vaccine and the recombinant zoster vaccine, meaning the study did not isolate risks associated with a specific vaccine type.
Frequently Asked Questions
- Is the shingles vaccine safe for people who have had HZO? The study shows that while there is a statistical increase in recurrence risk in the first eight weeks post-vaccination, the overall absolute incidence remains low.
- What symptoms should patients watch for after vaccination? Patients should monitor for signs of HZO recurrence, such as eye pain, redness, or vision changes, particularly within the first two months after receiving the vaccine.
- Should I delay my shingles vaccination if I have had HZO? The researchers suggest that clinicians should evaluate the timing of vaccination on a case-by-case basis, specifically considering how recently the HZO episode occurred.
Are you a healthcare provider or a patient navigating the timing of shingles vaccination? Share your questions or experiences in the comments below, or subscribe to our newsletter for the latest updates on clinical research and ocular health.
